StockDrifts LogoStockDrifts

JW Pharmaceutical 001060

Company
JW중외제약JW Pharmaceutical
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2026-01-01

JW Pharmaceutical (001060) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for JW Pharmaceutical is dated 2024-12-02; the most recent is 2026-01-01.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-09-10BUY기타
JW홀딩스
JW Holdings
-1.3M₩26,600+4.9%₩34.5B ($23.9M)
2026-09-10SELL전환등
JW홀딩스
JW Holdings
--1.1M₩26,600-4.9%₩28.3B ($19.6M)
2026-01-01BUY신규선임
이기환
Lee Ki-hwan
director9.4K₩25,800+47.3%₩242M ($168K)
2025-01-01BUY신규선임
윤희승
Heeseung Yoon
director188₩23,950+58.7%₩5M ($3K)
2024-12-02BUY신규선임
함은경
Ham Eun-kyung
CEO (bank president)1.1K₩23,250+63.4%₩26M ($18K)

Frequently asked questions

Who has been buying JW Pharmaceutical stock?
0 distinct insiders have filed 0 disclosed insider purchases in JW Pharmaceutical (001060), most recently on 2026-01-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does JW Pharmaceutical have?
JW Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-12-02 to 2026-01-01.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.